Search clinical trials for: Elagolix placebo

Total 53847 results

Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

Endometriosis

China
Qilu Pharmaceutical (Hainan) Co., Ltd.

Recruiting

A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain

Endometriosis

China
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids

United States, Puerto Rico
AbbVie

Active, not recruiting

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Puerto Rico
Bayer

Terminated

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb (SCHUMANN)

Endometriosis

Spain, Belgium, United States, Germany, Austria, Japan, Canada, Hungary, Bulgaria, Italy, China, Czechia, Finland, Norway, Poland, Slovakia, Estonia, Greece, Latvia, Lithuania
AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-I)

Endometriosis
AbbVie

Completed

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-II)

Endometriosis
AbbVie (prior sponsor, Abbott)
Neurocrine Biosciences

Completed

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Folliculogenesis

United States, Puerto Rico
AbbVie

Completed

Efficacy and Safety Study of Elagolix in Women With Endometriosis

Endometriosis, Pain
AbbVie

Completed

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

United States, Puerto Rico
Yale University
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cardiovascular Disease Risk in Women With Endometriosis

Endometriosis

United States
Yale University
Johns Hopkins University; University of Colorado, Denver; Northwestern University and other collaborators

Recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (PREGnant)

Infertility | Endometriosis

United States
Yale University
University of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaborators

Active, not recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)

Infertility | Endometriosis

United States
AbbVie

Completed

An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

Endometriosis, Pain
AbbVie

Completed

Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Endometriosis
AbbVie

Completed

Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain

Endometriosis
AbbVie

Completed

Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Endometriosis
AbbVie

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Endometriosis

United States, Canada, Puerto Rico
University of Southern California

Unknown

Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle

Ovulation; Failure or Lack of
Takeda

Completed

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Uterine Fibroids

Japan
AbbVie

Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada
AbbVie

Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada, Puerto Rico
AbbVie

Completed

Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis (PETAL)

Endometriosis
Takeda

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Uterine Fibroids

Japan
Yale University
Pfizer

Recruiting

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Icahn School of Medicine at Mount Sinai
AbbVie

Recruiting

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

Mild Autonomous Cortisol Excess

United States
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
AbbVie

Recruiting

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Endometriosis

United States, Puerto Rico
AbbVie

Completed

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada, Puerto Rico
Takeda

Completed

Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Uterine Fibroids

Japan
Medstar Health Research Institute

Active, not recruiting

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L (Magical)

Fibroid Uterus | Heavy Menstrual Bleeding

United States
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (SERENE)

Contraception

United States, Puerto Rico
AbbVie

Completed

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Uterine Fibroids | Heavy Uterine Bleeding
University of Miami
Varian Medical Systems

Not yet recruiting

The University of Miami Adapt (UAdapt) Trial

Prostate Cancer

United States
Sumitomo Pharma Switzerland GmbH

Recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk

United States
Sumitomo Pharma Switzerland GmbH

Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Endometriosis | Uterine Fibroids

United States
Wake Forest University Health Sciences
Stanford University; University of North Carolina, Chapel Hill

Completed

Elagolix for Fertility Enhancement Clinical Trial (EFFECT)

Endometriosis | Unexplained Infertility

United States
Myovant Sciences GmbH

Completed

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroids | Uterine Leiomyoma

United States, Italy, Poland, Czechia, Hungary, South Africa, Brazil, Chile
Myovant Sciences GmbH

Completed

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Belgium, Czechia, South Africa, Chile, Brazil, Hungary, Poland
Myovant Sciences GmbH

Completed

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis Related Pain

United States, Spain, Hungary, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Poland, Portugal, South Africa, Ukraine
ASKA Pharmaceutical Co., Ltd.

Completed

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

Endometriosis

Japan
NorthShore University HealthSystem
Pfizer

Not yet recruiting

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

Pelvic Pain

United States
Myovant Sciences GmbH

Completed

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis Related Pain

United States, Poland, Australia, Brazil, Chile, Czechia, Georgia, Italy, New Zealand, Romania, Sweden
Colorado Center for Reproductive Medicine
AbbVie

Active, not recruiting

Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis

Infertility | Endometriosis

United States
Main Line Health
Pfizer; Sumitomo Pharma America, Inc.

Not yet recruiting

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Endometriosis

United States
NYU Langone Health

Recruiting

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Myovant Sciences GmbH

Completed

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Italy, Poland, Brazil, South Africa, United Kingdom
Takeda

Completed

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Hormone Treatment-naïve Participants With Prostate Cancer

Japan
Myovant Sciences GmbH

Completed

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

Healthy

United States
Takeda

Completed

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Endometriosis

Japan

3

Subscribe